Fierce Biotech12d
Wave's DMD drug remains on track in 48-week data ahead of FDA push next year
As it gears up to submit an approval application next year, Wave Life Sciences has presented fresh phase 2 data showing its ...
BioWorld12d
Riding the Wave, exon skipper sails toward DMD filing
Wave Life Sciences Ltd. plans to file with the U.S. FDA for accelerated approval of WVE-N531, an exon skipping ...
pharmaphorum5d
Nippon Shinyaku’s DMD drug fails confirmatory trial
The exon-skipping drug was approved by the FDA for DMD patients with mutations in the dystrophin gene amenable to exon 53 skipping, a group that accounts for around 8% of the total DMD population.
The American Journal of Managed Care11d
WVE-N531 Shows Functional Benefits, Muscle Damage Reversal in DMD
WVE-N531 demonstrated statistically significant improvements in muscle biopsy measures and functional measures in patients ...
BioSpace12d
Wave’s Duchenne Exon-Skipper Reverses Muscle Damage in Mid-Stage Trial
WVE-N531, an oligonucleotide, elicited significant functional benefit and reversal of muscle damage in the Phase II ...